|
Jun 6
|
Gilead Says Bulevirtide With PegIFN Data 'Superior' to Bulevirtide Monotherapy; Achieves 46% Rate of Undetectable HDV RNA
|
|
Jun 6
|
Gilead’s seladelpar shows promise in primary biliary cholangitis trial
|
|
Jun 6
|
Gilead Announces New England Journal of Medicine Publication of Data that Demonstrate Bulevirtide with PegIFN Achieved Post-Treatment Undetectable HDV RNA
|
|
May 29
|
Buy Low, Hold Long: 2 Crushed Dividend Stocks To Buy For High Yields And Long-Term Gains
|
|
May 29
|
Gilead and Cartography enter deal to develop cancer therapies
|
|
May 28
|
Gilead Sciences Partners With White House for Early Cancer Detection Program "Biden Cancer Moonshot"
|
|
May 28
|
2 Beaten-Down Dividend Stocks to Buy and Hold For 10 Years
|
|
May 14
|
Kite Data at EHA 2024 Demonstrate Positive Patient Outcomes and Advances in Delivery of CAR T-cell Therapy
|
|
May 14
|
Gilead Sciences: Native Health Navigator Program Connects Tribes to Cancer Care
|
|
May 13
|
One stock is dragging down the S&P 500's earnings growth
|
|
May 9
|
Kite and Arcellx Continue Momentum with Advances in Anito-Cel Multiple Myeloma Program
|
|
May 9
|
Gilead's FOCUS Program Helps Zero In on Early HIV Detection
|
|
May 9
|
Decoding Gilead Sciences Inc (GILD): A Strategic SWOT Insight
|
|
May 7
|
Gilead Helps Put African Nation on Path To Eliminate Hepatitis C
|
|
May 7
|
Gilead and Kite Oncology to Highlight Broad and Diverse Oncology Portfolio at ASCO 2024
|
|
May 6
|
Bargain Hunting: 7 Stocks Near 52-Week Lows to Buy Before the Bounce Back
|
|
May 4
|
23 Most Profitable Stocks of the Last 12 Months
|
|
May 3
|
Forbes Has Listed Gilead as One of America’s Best Employers for Diversity
|
|
May 3
|
The Zacks Analyst Blog Highlights Gilead Sciences, GSK, Deciphera, Bristol Myers and Editas Medicine
|
|
May 2
|
Biotech Stock Roundup: GILD's GSK' Q1 Earnings, DCPH Soars on Acquisition News & More
|